Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)-Reference-Cited by-同舟云学术

Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)

Published:2011-02-27 Issue:3 Volume:28 Page:455-465
ISSN:1569-5794
Container-title:The International Journal of Cardiovascular Imaging
language:en
Short-container-title:Int J Cardiovasc Imaging

Author:

García-García Héctor M., ,Garg Scot,Brugaletta Salvatore,Morocutti Giorgio,Ratner Robert E.,Kolatkar Nikheel S.,Kravitz Barbara G.,Miller Diane M.,Huang Chun,Nesto Richard W.,Serruys Patrick W.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging

Link

http://www.springerlink.com/index/pdf/10.1007/s10554-011-9836-z

Reference36 articles.

1. Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ (2008) Assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history (approach): Study design and baseline characteristics. Am Heart J 156(6):1074–1079. doi: 10.1016/j.ahj.2008.07.025

2. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garcia-Garcia HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease. The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. doi: 10.1161/CIRCULATIONAHA.109.881003

3. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB (1998) The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32(3):584–589. doi: S0735-1097(98)00286-1

4. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, de Feyter PJ, van Domburg RT, Serruys PW (2004) Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: An evaluation from the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (research) study. Circulation 109(11):1366–1370. doi: 10.1161/01.CIR.0000121358.26097.06

5. Scheen AJ, Warzee F, Legrand VM (2004) Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 25(23):2167–2168; author reply 2168–2169. doi: 10.1016/j.ehj.2004.07.041

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes and restenosis;Cardiovascular Diabetology;2022-02-14

2. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective;Current Pharmaceutical Design;2019-09-30

3. Reversal of coronary atherosclerosis: Role of life style and medical management;Trends in Cardiovascular Medicine;2018-11

4. Exogenous SERP1 attenuates restenosis by restoring GLP-1 receptor activity in diabetic rats following vascular injury;Biomedicine & Pharmacotherapy;2018-07

5. Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials;Scientific Reports;2017-10-31